TUV SUD Acquires MSOURCE to Enter Life Science Clinical Research
TUV SUD has completed the acquisition of all shares of MSOURCE Medical Development to create a new T?V S?D Life Science business unit.
TUV SUD acquires MSOURCE to enter life science clinical research
TUV SUD has completed the acquisition of all shares of MSOURCE Medical Development to create a new TUV SUD Life Science business unit. MSOURCE will be the contract research organization (CRO) of this business unit, which will belong to the PEOPLE division of TUV SUD. TUV SUD’s dedication to product reliability, safety and quality now extends to the pharmaceutical and biotechnology industries. To the medical device industry, TUV SUD now additionally offers clinical research services.
MSOURCE employs more than 240 personnel, active in clinical trial management, data management, statistics, pharmacovigilance and quality assurance on behalf of pharmaceutical, biotechnology and medical device companies. Currently services are delivered from headquarters in Brussels/Kraainem and offices in the Netherlands, Germany, Poland, Spain and the UK.
“The opportunity to apply TUV SUD’s certification, testing and management skills to clinical research services is the main reason to make this important step forward,” said Prof. Dr. Peter Schaff, managing director of TUV SUD’s PEOPLE Division. “There is a distinct need for quality in each step of the clinical research process, while the complexity and global reach of clinical trials increase every year.
“We are creating an important new Contract Research Organization with the stability of a major company, combined with the flexibility and responsiveness of a mid size CRO,” said Dr. Adriaan Hart de Ruijter, co founder and managing director of MSOURCE. “We made the choice for TUV SUD because of a shared vision on quality and future strategy. The access to worldwide facilities and capital enables us to respond better to our client’s needs”. Dr. Hart de Ruyter assumes the role of managing director, TUV SUD Life Science, and will continue to lead the management team of MSOURCE as well as the further expansion to achieve global reach. MSOURCE will remain an independent organization and entity in the TUV SUD group. The headquarters of MSOURCE will remain in Kraainem, close to Brussels.
“Our employees will fit well into the PEOPLE division of TUV SUD. MSOURCE’s mission to deliver excellence in clinical research services is close to TUV SUD’s original corporate mission to support the design of technology for the benefit of people,” said Dr. Anne Jolie, co founder and Manager Pharmacovigilance & Medical Affairs at MSOURCE.
SOURCE TUV SUD
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
